GS
GSS.AU Genetic Signatures Ltd
- Market cap
- AUD 17.7M
- P/E
- -
- P/B
- 0.50x
- ROE
- -39.2%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is GSS.AU undervalued?
Graham numberThe Graham number of Genetic Signatures Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genetic Signatures Ltd fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-39.2%), below 10%.
ROA 1/1
Return on assets (-36.4%) is above the industry median (-36.5%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (30.5%) is above the industry median (12.5%).
Revenue Growth 0/2
Revenue shrank 5.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.9%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 2.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.5x) is below the industry median (3.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genetic Signatures Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. Genetic Signatures…
Full company profileGenetic Signatures Ltd financial statements
Genetic Signatures Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.06M | 4.99M | 7.02M | 11.3M | 28.3M | 35.4M | 16.9M | 9.77M | 15.9M | 14.5M |
| Gross Profit | 2.34M | 3.01M | 4.16M | -2.37M | 4.27M | 7.21M | -12.7M | 4.31M | 7.78M | -12.7M |
| Operating Income | -2.78M | -3.40M | -3.60M | -4.83M | 1.56M | 2.97M | -18.9M | -22.3M | -18.5M | -17.7M |
| EBITDA | -2.30M | -2.77M | -3.02M | -1.17M | 3.22M | 4.70M | -13.1M | -19.8M | -16.1M | -15.7M |
| Net Income | -2.67M | -3.25M | -3.49M | -2.09M | 1.76M | 3.06M | -14.1M | -17.9M | -20.1M | -14.0M |
| EPS | -0.03 | -0.03 | -0.03 | -0.02 | 0.01 | 0.02 | -0.10 | -0.11 | -0.09 | -0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 17.7M | 14.6M | 12.1M | 49.7M | 54.0M | 59.7M | 49.1M | 67.3M | 54.6M | 38.5M |
| Total Liabilities | 1.19M | 1.21M | 1.56M | 3.79M | 4.71M | 4.85M | 6.16M | 6.18M | 4.54M | 2.73M |
| Shareholders' Equity | 16.5M | 13.4M | 10.6M | 45.9M | 49.3M | 54.8M | 42.9M | 61.1M | 50.1M | 35.7M |
| Cash & Short-term Investments | 13.2M | 8.95M | 6.31M | 31.2M | 30.1M | 36.9M | 16.3M | 36.3M | 31.3M | 22.1M |
| Total Debt | - | - | 741K | 741K | 399K | 34.0K | - | 1.22M | 791K | 310K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.57M | -3.69M | -2.27M | -9.49M | 4.20M | 9.81M | -12.5M | -10.1M | -12.3M | -7.77M |
| Capital Expenditure | 1.01M | 519K | 610K | 2.35M | 4.98M | 2.99M | 8.09M | 4.79M | 902K | 1.05M |
| Free Cash Flow | -3.58M | -4.21M | -2.88M | -11.8M | -784K | 6.82M | -20.5M | -14.9M | -13.2M | -8.82M |
| Ratios | ||||||||||
| ROE | -16.2% | -24.3% | -33.0% | -4.5% | 3.6% | 5.6% | -32.7% | -29.2% | -40.1% | -39.2% |
| ROA | -15.1% | -22.3% | -28.8% | -4.2% | 3.2% | 5.1% | -28.6% | -26.5% | -36.8% | -36.4% |
| Net Profit Margin | -65.8% | -65.2% | -49.7% | -18.5% | 6.2% | 8.6% | -83.0% | -182.9% | -126.4% | -96.9% |
| Debt to Equity | - | - | 0.07x | 0.02x | 0.01x | 0.00x | - | 0.02x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genetic Signatures Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 24.0K | 0.00 | - |
| 2022 | AUD 110K | 0.00 | 3.6% |
| 2021 | AUD 202K | 0.00 | 11.5% |
| 2020 | AUD 34.8M | 0.27 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genetic Signatures Ltd
- Insiders 28.24%
- Institutions 40.80%
- Public & others 30.97%
- Shares outstanding 227M
- Free float 139M
Top funds holding GSS.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Alps Series Tr-Seven Canyons World Innovators Fd | 1.10M | 0.77% | - | Dec 2020 |
Genetic Signatures Ltd company profile
- Company name
- Genetic Signatures Ltd
- Ticker
- GSS.AU
- ISIN
- AU000000GSS4
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Fiscal year end
- June
- Address
- Heart Research Institute, Newtown, NSW, Australia, 2042
- Phone
- 61 2 9870 7580
- Website
- geneticsignatures.com
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
Genetic Signatures Ltd management
4- Mr. Michael Anton Aicher BSc, M.B.A.Executive Chairman & Executive Director of US Operations · born 1960
- Ms. Maria Halasz BSc, MBAChief Executive Officer
- Mr. Christopher M. Abbott A.M., F.C.A., Ph.D., Ph.D., (Hon)Founder & Chairman Emeritus
- Ms. Angela WangFinancial Controller